Faron

Faron

Pharmaceutical Manufacturing

A CLEVER Approach to Fight Cancer.

About us

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.

Sivusto
https://www.faron.com
Toimiala
Pharmaceutical Manufacturing
Yrityksen koko
11–50 työntekijää
Päätoimipaikka
Turku
Tyyppi
Public Company
Perustettu
2007
Erityisosaaminen

Sijainnit

Työntekijät Faron

Päivitykset

Samankaltaisia sivuja

Rahoitus

Faron 10 Kierroksia yhteensä

Viimeinen kierros

Avustus

1 500 000,00 $

Katso lisätietoja crunchbasesta